Clinical trials conducted in China have assessed the feasibility and safety of anti-PD-1 antibody (camrelizumab) alone or in combination with decitabine and/or chemotherapy in a variety of refractory malignancies including BC (NCT02961101). The gene discussed is PDCD1; the disease is breast cancer.